Sponsors › The University of Texas Health Science Center at San Antonio

The University of Texas Health Science Center at San Antonio

Every GLP‑1 and incretin trial, approval and scheduled result we hold for The University of Texas Health Science Center at San Antonio, drawn from ClinicalTrials.gov and Drugs@FDA.

The University of Texas Health Science Center at San Antonio is an academic or hospital sponsor, not a drug company with 8 trials in the incretin class on file here, across 3 molecules. The programme is split between 1 early-stage trial and 7 in phase 3 or later. The next scheduled result is 2027-04-01.

Molecules: exenatide · semaglutide · tirzepatide
Trials on file: 8
Active trials: 2
Results scheduled: 0
Approved FDA submissions: 0

Trials on file

All 8 incretin trials recorded for this sponsor, active first.

Drug	Trial	Status	Phase	Participants
tirzepatide	Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes NCT06246799	Recruiting	P3	256
tirzepatide	Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults NCT06811324	Recruiting	P2	20
exenatide	Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM NCT01107717	Completed	P4	318
exenatide	Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria NCT03331289	Completed	P4	107
exenatide	Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM NCT02981069	Completed	P4	90
exenatide	Effect of Pioglitazone and Exenatide on Body Weight and Beta Cell Function NCT00845182	Completed	P4	43
semaglutide	Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults NCT05786521	Completed	P4	20
exenatide	Acute Effect of Exenatide on Brain Glucose Metabolism NCT01588418	Completed	P4	15